Raymond James analyst Danielle Brill maintains $Sage Therapeutics (SAGE.US)$ with a hold rating.
According to TipRanks data, the analyst has a success rate of 48.3% and a total average return of 7.3% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Sage Therapeutics (SAGE.US)$'s main analysts recently are as follows:
Sage Therapeutics' Phase 2 LIGHTWAVE study, which assessed dalzanemdor in Alzheimer's disease, failed to achieve its primary goal. Subsequently, the company has decided not to pursue further development of the drug for this indication. Despite the setback, Sage anticipates topline results from another Phase 2 trial, DIMENSION, studying dalzanemdor in Huntington's disease later in the year. Initial encouraging findings from the SURVEYOR trial do offer some clinical substantiation; however, it is emphasized that substantial clinical validation remains essential to mitigate the risks associated with the program.
Sage Therapeutics' Phase 2 LIGHTWAVE study of dalzanemdor for mild AD/MCI did not meet the primary endpoint of showing a significant improvement from baseline in WAIS-IV score. As the potential of dalzanemdor was not previously factored into projections, there are no changes needed to forecasts. Sage has decided to halt further development of dalzanemdor for Alzheimer's disease, though it still expects data from the DIMENSION trial for Huntington's disease by the fourth quarter of 2024. However, due to previous setbacks with dalzanemdor, there is a cautious outlook on the upcoming results for Huntington's disease.
Sage Therapeutics recently disclosed the unsuccessful outcome of the phase 2 LIGHTWAVE trial concerning dalzanemdor for treating Alzheimer's disease. This development is likely to shift the entire investor attention towards the prospects of Zurzuvae moving forward.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
